Loading clinical trials...
Loading clinical trials...
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, ede...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
University of Michigan
NCT07516964 · Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, and more
NCT07267026 · FSGS, MCD
NCT07220083 · Focal Segmental Glomerulosclerosis
NCT07219121 · Proteinuria, Immunoglobulin A (IgA) Nephropathy, and more
NCT06090227 · Focal Segmental Glomerulosclerosis
University of Michigan
Ann Arbor, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions